{"filing":{"accession_number":"0001213900-26-064804","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"ea0293111-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026064804/ea0293111-8k_silo.htm"},"events":[{"id":7211,"run_id":6325,"accession_number":"0001213900-26-064804","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Silo Pharma, Inc. implemented a 1-for-15 reverse stock split of its Common Stock, effective June 2, 2026, which proportionately reduced the Company's issued, outstanding, and authorized shares. This capital structure change affects share price, option and warrant exercise prices, and equity plan reserves, and may reflect efforts to address listing compliance requirements.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4033,"accession_number":"0001213900-26-064804","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.55,"reasoning":"Item 3.03 discloses a material modification to rights of security holders and incorporates Item 5.03 by reference. Without access to Item 5.03's full content, the nature of the modification cannot be precisely determined. Item 5.03 typically covers amendments to articles of incorporation or bylaws. The disclosure is material by definition (Item 3.03 is reserved for material modifications), but the specific event type cannot be confidently assigned without seeing the referenced Item 5.03 content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4034,"accession_number":"0001213900-26-064804","item_number":"5.03","item_title":"Amendments","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a 1-for-15 reverse stock split that became effective on June 2, 2026, affecting the Company's issued, outstanding, and authorized shares of Common Stock. While reverse stock splits are structural corporate actions that affect share count and trading mechanics, this event does not fit neatly into the more specific taxonomy categories (it is not a bylaw amendment per se, nor a change in fiscal year, nor a dilutive issuance). The reverse split is material to investors as it affects share price, exercise prices of options and warrants, and equity plan reserves, and signals potential delisting risk mitigation efforts typical of Nasdaq-listed companies. Classified as other_material because the taxonomy lacks a dedicated reverse split category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4035,"accession_number":"0001213900-26-064804","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a 1-15 reverse stock split that affects the Company's outstanding shares and registration statements. While the Item 8.01 text itself is largely boilerplate incorporation-by-reference language, the reference to Item 5.03 (which typically covers amendments to articles of incorporation or bylaws) combined with the explicit mention of a \"1-15 Reverse Stock Split\" and its proportionate reduction of undistributed shares indicates a material capital structure change. This does not fit neatly into the more specific event categories but would materially affect investor assessment of share count and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4033,"accession_number":"0001213900-26-064804","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.55,"reasoning":"Item 3.03 discloses a material modification to rights of security holders and incorporates Item 5.03 by reference. Without access to Item 5.03's full content, the nature of the modification cannot be precisely determined. Item 5.03 typically covers amendments to articles of incorporation or bylaws. The disclosure is material by definition (Item 3.03 is reserved for material modifications), but the specific event type cannot be confidently assigned without seeing the referenced Item 5.03 content.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-03"},{"id":4034,"accession_number":"0001213900-26-064804","item_number":"5.03","item_title":"Amendments","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a 1-for-15 reverse stock split that became effective on June 2, 2026, affecting the Company's issued, outstanding, and authorized shares of Common Stock. While reverse stock splits are structural corporate actions that affect share count and trading mechanics, this event does not fit neatly into the more specific taxonomy categories (it is not a bylaw amendment per se, nor a change in fiscal year, nor a dilutive issuance). The reverse split is material to investors as it affects share price, exercise prices of options and warrants, and equity plan reserves, and signals potential delisting risk mitigation efforts typical of Nasdaq-listed companies. Classified as other_material because the taxonomy lacks a dedicated reverse split category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-03"},{"id":4035,"accession_number":"0001213900-26-064804","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a 1-15 reverse stock split that affects the Company's outstanding shares and registration statements. While the Item 8.01 text itself is largely boilerplate incorporation-by-reference language, the reference to Item 5.03 (which typically covers amendments to articles of incorporation or bylaws) combined with the explicit mention of a \"1-15 Reverse Stock Split\" and its proportionate reduction of undistributed shares indicates a material capital structure change. This does not fit neatly into the more specific event categories but would materially affect investor assessment of share count and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:43:52.751594+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-03"}]}